Online:
Visits:
Stories:
Profile image
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Spinal Cord Injury -under Development by Companies, H2 2016

Friday, January 6, 2017 7:20
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Spinal cord injury (SCI) is defined as damage or trauma caused to the spinal cord. SCI can lead to loss or impaired function resulting in reduced mobility or feeling. It is usually caused by trauma, transverse myelitis, polio, spina bifida or Friedreich’s ataxia. Signs and symptoms of spinal cord injury include extreme back pain or pressure in the neck, head or back, paralysis in any part of the body, numbness, tingling or loss of sensation in the hands, fingers, feet or toes, loss of bladder or bowel control, difficulty in walking and impaired breathing after injury.

Report Highlights:

This report Pharmaceutical and Healthcare latest pipeline guide Spinal Cord Injury – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Spinal Cord Injury (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

 

The Spinal Cord Injury (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Spinal Cord Injury and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 10, 7, 23 and 6 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 15 and 2 molecules, respectively. Spinal Cord Injury.

Spinal Cord Injury (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis..

For more information about this report at http://www.reportsweb.com/spinal-cord-injury-pipeline-review-h2-2016

Scope:

- The pipeline guide provides a snapshot of the global therapeutic landscape of Spinal Cord Injury (Central Nervous System).

- The pipeline guide reviews pipeline therapeutics for Spinal Cord Injury (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Spinal Cord Injury (Central Nervous System) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Spinal Cord Injury (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Spinal Cord Injury (Central Nervous System)

Request a sample copy at http://www.reportsweb.com/inquiry&RW0001485312/sample

Reasons to buy:

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Spinal Cord Injury (Central Nervous System).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Spinal Cord Injury (Central Nervous System) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Companies profiles

AbbVie Inc

Acorda Therapeutics Inc

Asterias Biotherapeutics, Inc.

Asubio Pharma Co Ltd

Athersys Inc

BioArctic Neuroscience AB

BioAxone BioSciences Inc

Genervon Biopharmaceuticals LLC

Histocell SL

Kadimastem Ltd

Kringle Pharma Inc

Lpath Inc

MandalMed Inc

Mapreg SAS

Medgenics Inc

Neuralstem Inc

Neuronax SAS

New World Laboratories Inc

Omeros Corp

PharmatrophiX, Inc.

Pharmicell Co Ltd

Protagenic Therapeutics Inc.

Q Therapeutics Inc

Remedy Pharmaceuticals Inc

RespireRx Pharmaceuticals Inc

SanBio Inc

Stemedica Cell Technologies Inc

TissueGene Inc

TRB Chemedica International SA

Tumorend LLC

Vertex Pharmaceuticals Inc

Vicore Pharma AB

Ask for Discount at http://www.reportsweb.com/inquiry&RW0001485312/discount

Few Points from List of Tables

Number of Products under Development for Spinal Cord Injury, H2 2016 14

Number of Products under Development for Spinal Cord Injury – Comparative Analysis, H2 2016 15

Number of Products under Development by Companies, H2 2016 16

Number of Products under Development by Companies, H2 2016 (Contd..1) 17

Number of Products under Development by Companies, H2 2016 (Contd..2) 18

Number of Products under Investigation by Universities/Institutes, H2 2016 19

Comparative Analysis by Late Stage Development, H2 2016 20

Comparative Analysis by Clinical Stage Development, H2 2016 21

Comparative Analysis by Early Stage Development, H2 2016 22

Products under Development by Companies, H2 2016 23

Products under Development by Companies, H2 2016 (Contd..1) 24

Products under Development by Companies, H2 2016 (Contd..2) 25

Products under Investigation by Universities/Institutes, H2 2016 26

Spinal Cord Injury – Pipeline by AbbVie Inc, H2 2016 27

Spinal Cord Injury – Pipeline by Acorda Therapeutics Inc, H2 2016 28

Spinal Cord Injury – Pipeline by Asterias Biotherapeutics, Inc., H2 2016 29

Spinal Cord Injury – Pipeline by Asubio Pharma Co Ltd, H2 2016 30

Spinal Cord Injury – Pipeline by Athersys Inc, H2 2016 31

Spinal Cord Injury – Pipeline by BioArctic Neuroscience AB, H2 2016 32

Contact Us:                 
Call: +1-646-491-9876
Email: sales@reportsweb.com

 

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories
 

Featured

 

Top Global

 

Top Alternative

 

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.